Heart Rate and Heart Rate Difference Predicted the Efficacy of Metoprolol on Postural Tachycardia Syndrome in Children and Adolescents

• Published in: The Journal of pediatrics Vol. 224; pp. 110 - 114
• Main Authors: Wang, Shuo, Zou, Runmei, Cai, Hong, Wang, Yuwen, Ding, Yiyi, Tan, Chuanmei, Yang, Maosheng, Li, Fang, Wang, Cheng
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2020
• Subjects: adolescents; Adrenergic beta-1 Receptor Antagonists - pharmacology; Adrenergic beta-1 Receptor Antagonists - therapeutic use; Case-Control Studies; Child; children; Female; heart rate; Heart Rate - drug effects; heart rate difference; Humans; Male; metoprolol; Metoprolol - pharmacology; Metoprolol - therapeutic use; Postural Orthostatic Tachycardia Syndrome - drug therapy; Postural Orthostatic Tachycardia Syndrome - physiopathology; postural tachycardia syndrome; Retrospective Studies; Sensitivity and Specificity; Standing Position; postural tachycardia syndrome; heart rate; CNP; metoprolol; heart rate difference; children; adolescents; ECG; HR; POTS; AUC; HUTT
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/j.jpeds.2020.05.017

To evaluate the ability of heart rate (HR) and HR difference during head-up tilt test (HUTT) and to predict clinical improvement related to metoprolol treatment in children and adolescents with postural tachycardia syndrome (POTS). This was a retrospective cohort study. A total of 53 subjects (27 male, aged 6-12 years old, mean age 11.79 ± 1.50 years old) with POTS treated with metoprolol were involved from July 2012 to September 2019. In total, 52 subjects who underwent health examination during the same period were matched as the control group. Subjects in both groups underwent HUTT. The HR distance between 5 minutes and 0 minutes (HR difference 5) and between 10 minutes and 0 minutes (HR difference 10) during HUTT was calculated. The POTS group was significantly greater than the control group in HR 5, HR 10, HR difference 5, and HR difference 10 (P < .01). There was no statistical difference in HR 0 between the 2 groups (P > .05). In total, 53 subjects with POTS were followed up for 96.0 (IQR, 40.5, 134.5) days during treatment with metoprolol. HUTT results demonstrated that 58.49% of subjects with POTS had a response and symptom scores were reduced after intervention. HR and HR difference were useful in predicting the efficacy of metoprolol on POTS. When HR 5, HR 10, HR difference 5, and HR difference 10, respectively, were ≥110, 112, 34, and 37 beats/min, the sensitivity and specificity were 82.50% and 69.23%, 84.62% and 69.70%, 85.29% and 89.47%, and 97.56% and 64.86%, respectively. HR and HR difference are helpful to predict the efficacy of metoprolol on POTS in children and adolescents.